Taken together, these in vitro and in vivo studies provide new insights into the mechanism of antitumor action of HB-19, and suggest that several inhibitory pathways could be operating in order to coordinate the delay in the development of melanoma in HB-19 treated RET mice. The gene discussed is RET; the disease is melanoma.